Karen E Knudsen

List of Publications by Year in Descending Order

150 papers	11,806 citations	61 h-index	106 g-index
160 ext. papers	14,038 ext. citations	10.3 avg, IF	6.28 L-index

#	Paper	IF	Citations
150	Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. *Oncogene*, **2021**,	9.2	1
149	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. *Clinical Cancer Research*, **2021**, 27, 3017-3027	12.9	7
148	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. *Cancer Discovery*, **2021**, 11, 2334-2353	24.4	9
147	The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. *Journal of Personalized Medicine*, **2021**, 11,	3.6	1
146	The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22. *EMBO Journal*, **2021**, 40, e102509	13	1
145	Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities. *Clinical Cancer Research*, **2021**, 27, 933-936	12.9	10
144	Targeting the p300/CBP Axis in Lethal Prostate Cancer. *Cancer Discovery*, **2021**, 11, 1118-1137	24.4	41
143	Differential expression of V3 and V6 integrins in prostate cancer progression. *PLoS ONE*, **2021**, 16, e0244985	3.7	5
142	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. *Nature Communications*, **2021**, 12, 401	17.4	15
141	Prostate cancer. *Nature Reviews Disease Primers*, **2021**, 7, 9	51.1	72
140	Relevance of pRB Loss in Human Malignancies. *Clinical Cancer Research*, **2021**,	12.9	2
139	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. *Urologic Clinics of North America*, **2021**, 48, 339-347	2.9	2
138	Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. *Cancer Communications*, **2021**,	9.4	1
137	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *Journal of Clinical Oncology*, **2020**, 38, 2798-2811	2.2	80
136	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. *Nature Reviews Urology*, **2020**, 17, 292-307	5.5	30
135	Double Trouble: Concomitant and Depletion Evokes Aggressive Phenotypes. *Clinical Cancer Research*, **2020**, 26, 1784-1786	12.9	2
134	USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair. *Cancer Research*, **2020**, 80, 430-443	10.1	22

133	Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. *International Journal of Cancer*, **2020**, 146, 2047-2058	7.5	9
132	The DNA methylation landscape of advanced prostate cancer. *Nature Genetics*, **2020**, 52, 778-789	36.3	71
131	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. *Science Advances*, **2019**, 5, eaax6352	14.3	17
130	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. *Clinical Cancer Research*, **2019**, 25, 4290-4299	12.9	15
129	Cancer and the Circadian Clock. *Cancer Research*, **2019**, 79, 3806-3814	10.1	63
128	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. *Clinical Cancer Research*, **2019**, 25, 6916-6924	12.9	94
127	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. *Clinical Cancer Research*, **2019**, 25, 5623-5637	12.9	13
126	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. *Clinical Cancer Research*, **2019**, 25, 5608-5622	12.9	10
125	Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. *Prostate*, **2019**, 79, 333-339	4.2	41
124	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. *International Journal of Cancer*, **2019**, 144, 1151-1159	7.5	11
123	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2019**, 25, 687-697	12.9	26
122	DNA Damage Response in Prostate Cancer. *Cold Spring Harbor Perspectives in Medicine*, **2019**, 9,	5.4	16
121	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. *Molecular Pharmaceutics*, **2018**, 15, 1778-1790	5.6	2
120	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2018**, 24, 1402-1414	12.9	21
119	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell*, **2018**, 174, 758-769.e9	56.2	234
118	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. *Clinical Cancer Research*, **2018**, 24, 4201-4214	12.9	49
117	A patient-derived explant (PDE) model of hormone-dependent cancer. *Molecular Oncology*, **2018**, 12, 1608-1622	7.9	54
116	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. *Cell*, **2018**, 174, 1200-1215.e20	56.2	66

115	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. *European Urology Oncology*, **2018**, 1, 325-337	6.7	23
114	Differential impact of RB status on E2F1 reprogramming in human cancer. *Journal of Clinical Investigation*, **2018**, 128, 341-358	15.9	58
113	Splice Variants and Phosphorylated Isoforms of Cyclin D1 in Tumorigenesis. *Current Cancer Research*, **2018**, 91-109	0.2	
112	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas and. *Molecular Cancer Therapeutics*, **2018**, 17, 84-95	6.1	11
111	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *Journal of Clinical Oncology*, **2018**, 36, 414-424	2.2	107
110	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. *Journal of Clinical Oncology*, **2018**, 36, 991-999	2.2	117
109	PARP-1 regulates DNA repair factor availability. *EMBO Molecular Medicine*, **2018**, 10,	12	35
108	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E9298-E9307	11.5	50
107	Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. *Cancer Research*, **2017**, 77, 2439-2452	10.1	24
106	Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. *Cancer Cell*, **2017**, 31, 471-473	24.3	5
105	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of Reversion Mutations Associated with Resistance to PARP Inhibitors. *Cancer Discovery*, **2017**, 7, 999-1005	24.4	158
104	PARP Inhibitors in Prostate Cancer. *Current Treatment Options in Oncology*, **2017**, 18, 37	5.4	42
103	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. *Cell Reports*, **2017**, 19, 2045-2059	10.6	72
102	RB Loss Promotes Prostate Cancer Metastasis. *Cancer Research*, **2017**, 77, 982-995	10.1	47
101	Posttranscriptional Regulation of mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. *Cancer Research*, **2017**, 77, 5011-5025	10.1	40
100	Detection of Activating Estrogen Receptor Gene () Mutations in Single Circulating Tumor Cells. *Clinical Cancer Research*, **2017**, 23, 6086-6093	12.9	50
99	Cell cycle-coupled expansion of AR activity promotes cancer progression. *Oncogene*, **2017**, 36, 1655-1668	9.2	26
98	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. *JAMA Oncology*, **2016**, 2, 471-80	13.4	38

97	Linking DNA Damage and Hormone Signaling Pathways in Cancer. *Trends in Endocrinology and Metabolism*, **2016**, 27, 216-225	8.8	42
96	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. *Urology Case Reports*, **2016**, 9, 51-54	0.5	
95	Cell-cycle-dependent regulation of androgen receptor function. *Endocrine-Related Cancer*, **2015**, 22, 249-64	5.7	21
94	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. *Cancer Cell*, **2015**, 28, 97-113	24.3	116
93	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. *Neoplasia*, **2015**, 17, 385-99	6.4	156
92	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. *Molecular Cell*, **2015**, 58, 925-34	14.6	102
91	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1106-15	11.5	307
90	Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. *Clinical Cancer Research*, **2015**, 21, 795-807	12.9	75
89	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *New England Journal of Medicine*, **2015**, 373, 1697-708	59.2	1345
88	Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. *Molecular Cancer Research*, **2015**, 13, 1591-601	6.6	30
87	Consequence of the tumor-associated conversion to cyclin D1b. *EMBO Molecular Medicine*, **2015**, 7, 628-47	12	13
86	Models of neuroendocrine prostate cancer. *Endocrine-Related Cancer*, **2015**, 22, R33-49	5.7	35
85	Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. *Cancer Research*, **2014**, 74, 31-7	10.1	38
84	PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. *Cancer Research*, **2014**, 74, 1651-60	10.1	204
83	AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. *EMBO Molecular Medicine*, **2014**, 6, 439-41	12	5
82	Beyond DNA repair: DNA-PK function in cancer. *Cancer Discovery*, **2014**, 4, 1126-39	24.4	141
81	Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 1038-1046	4	124
80	The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. *Clinical Cancer Research*, **2014**, 20, 5468-5482	12.9	15

79	Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. *Molecular Endocrinology*, **2014**, 28, 442-57		34
78	Fusing transcriptomics to progressive prostate cancer. *American Journal of Pathology*, **2014**, 184, 2608-19	3.8	
77	The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. *Neoplasia*, **2014**, 16, 900-8	6.4	187
76	Hormone whodunit: clues for solving the case of intratumor androgen production. *Clinical Cancer Research*, **2014**, 20, 5343-5	12.9	2
75	USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. *Cancer Research*, **2014**, 74, 272-86	10.1	68
74	Transcriptional roles of PARP1 in cancer. *Molecular Cancer Research*, **2014**, 12, 1069-80	6.6	99
73	AR function in promoting metastatic prostate cancer. *Cancer and Metastasis Reviews*, **2014**, 33, 399-411	9.6	52
72	Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. *Neoplasia*, **2013**, 15, 1207-17	6.4	39
71	Molecular pathogenesis and progression of prostate cancer. *Seminars in Oncology*, **2013**, 40, 244-58	5.5	78
70	The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2). *Journal of Biological Chemistry*, **2013**, 288, 24234-46	5.4	59
69	Ex vivo culture of human prostate tissue and drug development. *Nature Reviews Urology*, **2013**, 10, 483-7	5.5	96
68	Beyond the Cell Cycle: Implications of D-type Cyclin Deregulation in Prostate Cancer **2013**, 461-477		
67	IGF2 revs the steroidogenesis engine. *Endocrine-Related Cancer*, **2013**, 20, C19-21	5.7	1
66	Aberrant BAF57 signaling facilitates prometastatic phenotypes. *Clinical Cancer Research*, **2013**, 19, 2657-67	10.9	29
65	A hormone-DNA repair circuit governs the response to genotoxic insult. *Cancer Discovery*, **2013**, 3, 1254-71	14.4	215
64	Targeting cell cycle and hormone receptor pathways in cancer. *Oncogene*, **2013**, 32, 5481-91	9.2	82
63	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. *Journal of Clinical Investigation*, **2013**, 123, 493-508	15.9	33
62	The role of tumor suppressor dysregulation in prostate cancer progression. *Current Drug Targets*, **2013**, 14, 460-71	3	13

61	The AR dependent cell cycle: mechanisms and cancer relevance. *Molecular and Cellular Endocrinology*, **2012**, 352, 34-45	4.4	35
60	Dual roles of PARP-1 promote cancer growth and progression. *Cancer Discovery*, **2012**, 2, 1134-49	24.4	260
59	Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. *Clinical Cancer Research*, **2012**, 18, 3562-70	12.9	85
58	mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. *Endocrine-Related Cancer*, **2012**, 19, 1-12	5.7	44
57	Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. *Cancer Research*, **2012**, 72, 1248-59	10.1	28
56	Cyclin D1 goes metabolic: dual functions of cyclin D1 in regulating lipogenesis. *Cell Cycle*, **2012**, 11, 3533-4	4.7	6
55	Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance. *Cancer Research*, **2012**, 72, IA9-IA9	10.1	
54	FOXA1: master of steroid receptor function in cancer. *EMBO Journal*, **2011**, 30, 3885-94	13	133
53	Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. *International Journal of Biochemistry and Cell Biology*, **2011**, 43, 1318-29	5.6	14
52	Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. *Expert Review of Endocrinology and Metabolism*, **2011**, 6, 483-493	4.1	38
51	Postprostatectomy radiation therapy: an evidence-based review. *Future Oncology*, **2011**, 7, 1429-40	3.6	12
50	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. *Endocrine-Related Cancer*, **2011**, 18, 333-45	5.7	202
49	The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. *Cell Cycle*, **2011**, 10, 2497-503	4.7	186
48	Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. *Journal of Biological Chemistry*, **2011**, 286, 8117-8127	5.4	35
47	Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. *Nature Reviews Urology*, **2011**, 8, 562-8	5.5	31
46	Androgen Receptor Regulation of Prostate Cancer Progression and Metastasis **2011**, 277-309		
45	Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. *Endocrinology*, **2010**, 151, 896-908	4.8	41
44	Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. *Cancer Research*, **2010**, 70, 3975-84	10.1	62

43	Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. *Cancer Research*, **2010**, 70, 229-39	10.1	122
42	RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. *Cell Cycle*, **2010**, 9, 4153-63	4.7	131
41	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. *Trends in Endocrinology and Metabolism*, **2010**, 21, 315-24	8.8	220
40	The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. *Journal of Clinical Investigation*, **2010**, 120, 4478-92	15.9	223
39	Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. *Molecular and Cellular Biology*, **2009**, 29, 6170-81	4.8	35
38	Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. *Clinical Cancer Research*, **2009**, 15, 4792-8	12.9	242
37	Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. *Cancer Research*, **2009**, 69, 8223-30	10.1	90
36	Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. *Clinical Cancer Research*, **2009**, 15, 5338-49	12.9	72
35	Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. *Oncogene*, **2009**, 28, 1016-27	9.2	20
34	Tailoring to RB: tumour suppressor status and therapeutic response. *Nature Reviews Cancer*, **2008**, 8, 714-24	31.3	263
33	2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways. *Molecular Cancer Research*, **2008**, 6, 1507-20	6.6	11
32	The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. *Cancer Research*, **2008**, 68, 10154-62	10.1	62
31	Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. *Cancer Research*, **2008**, 68, 4551-8	10.1	63
30	Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. *Cancer Research*, **2008**, 68, 5628-38	10.1	53
29	AR, the cell cycle, and prostate cancer. *Nuclear Receptor Signaling*, **2008**, 6, e001	1	248
28	Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer **2008**, 63-81		
27	Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. *Environmental Health Perspectives*, **2007**, 115, 1646-53	8.4	29
26	An evaluation of evidence for the carcinogenic activity of bisphenol A. *Reproductive Toxicology*, **2007**, 24, 240-52	3.4	212

25	Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. *Cancer Research*, **2007**, 67, 6192-203	10.1	65
24	The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. *Cell Cycle*, **2007**, 6, 1307-13	4.7	30
23	The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. *Journal of Clinical Investigation*, **2007**, 117, 218-28	15.9	152
22	Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. *Cancer Research*, **2006**, 66, 11998-2008	10.1	20
21	Androgen receptor corepressors and prostate cancer. *Endocrine-Related Cancer*, **2006**, 13, 979-94	5.7	61
20	Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. *Molecular Cancer Therapeutics*, **2006**, 5, 3181-90	6.1	66
19	Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2190-5	11.5	112
18	Retinoblastoma tumor suppressor: where cancer meets the cell cycle. *Experimental Biology and Medicine*, **2006**, 231, 1271-81	3.7	71
17	The cyclin D1b splice variant: an old oncogene learns new tricks. *Cell Division*, **2006**, 1, 15	2.8	52
16	A central domain of cyclin D1 mediates nuclear receptor corepressor activity. *Oncogene*, **2005**, 24, 431-44	9.2	57
15	BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. *Molecular and Cellular Biology*, **2005**, 25, 2200-15	4.8	105
14	Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. *Cancer Research*, **2005**, 65, 54-65	10.1	66
13	2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. *Molecular Pharmacology*, **2004**, 66, 502-11	4.3	82
12	Differential requirement of SWI/SNF for androgen receptor activity. *Journal of Biological Chemistry*, **2003**, 278, 30605-13	5.4	84
11	Specificity of cyclin D1 for androgen receptor regulation. *Cancer Research*, **2003**, 63, 4903-13	10.1	57
10	Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. *Journal of Biological Chemistry*, **2002**, 277, 4782-9	5.4	90
9	Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. *Journal of Biological Chemistry*, **2002**, 277, 2207-15	5.4	107
8	Androgen Mediated Regulation of the G1-S Transition in Prostate Cancer **2002**, 91-110		

7	The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. *Molecular Cancer Therapeutics*, **2002**, 1, 515-24	6.1	121
6	Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. *Molecular and Cellular Biology*, **2001**, 21, 4032-45	4.8	52
5	RB-dependent S-phase response to DNA damage. *Molecular and Cellular Biology*, **2000**, 20, 7751-63	4.8	199
4	The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. *Oncogene*, **1999**, 18, 5239-45	9.2	53
3	Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. *Journal of Biological Chemistry*, **1999**, 274, 27632-41	5.4	61
2	Hus1p, a conserved fission yeast checkpoint protein, interacts with Rad1p and is phosphorylated in response to DNA damage. *EMBO Journal*, **1998**, 17, 2055-66	13	104
1	Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. *Journal of Biological Chemistry*, **1998**, 273, 20213-22	5.4	147